Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?

At StockStory, we dig beneath the surface of price movements to uncover whether a company's fundamentals justify its current valuation or suggest hidden potential. That said, here is one stock poised to prove the bears wrong and two facing legitimate challenges.

Two Stocks to Sell:

Arhaus (ARHS)

One-Month Return: -19.8%

With an aesthetic that features natural materials such as reclaimed wood, Arhaus (NASDAQ: ARHS) is a high-end furniture retailer that sells everything from sofas to rugs to bookcases.

Why Does ARHS Worry Us?

1. Poor same-store sales performance over the past two years indicates it’s having trouble bringing new shoppers into its brick-and-mortar locations
2. Revenue base of $1.38 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
3. Earnings per share fell by 22% annually over the last three years while its revenue grew, partly because it diluted shareholders

Arhaus is trading at $7.11 per share, or 14.6x forward P/E. Read our free research report to see why you should think twice about including ARHS in your portfolio.

Xerox (XRX)

One-Month Return: -23.4%

Pioneering the modern office copier and inventing technologies like Ethernet and the laser printer, Xerox (NASDAQ: XRX) provides document management systems, printing technology, and workplace solutions to businesses of all sizes across the globe.

Why Should You Sell XRX?

1. Sales were flat over the last five years, indicating it’s failed to expand this cycle
2. 5.5 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
3. High net-debt-to-EBITDA ratio of 8× increases the risk of forced asset sales or dilutive financing if operational performance weakens

At $1.42 per share, Xerox trades at 3.1x forward P/E. Check out our free in-depth research report to learn more about why XRX doesn’t pass our bar.

One Stock to Watch:

Stryker (SYK)

One-Month Return: -7.3%

With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.

Why Are We Fans of SYK?

1. Core business can prosper without any help from acquisitions as its organic revenue growth averaged 10.2% over the past two years
2. Economies of scale give it more fixed cost leverage than its smaller competitors
3. Incremental sales over the last five years boosted profitability as its annual earnings per share growth of 12.9% outstripped its revenue performance

Stryker’s stock price of $345.56 implies a valuation ratio of 23.3x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.

Stocks We Like Even More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.